Bcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study Group - Concepedia

Concepedia

Publication | Closed Access

Bcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study Group

596

Citations

15

References

2006

Year

Agop Y. Bedikian, Michael Millward, Hubert Pehamberger, Robert M. Conry, Martin Gore, Uwe Trefzer, Anna C. Pavlick, Ronald C. DeConti, Evan M. Hersh, Peter Hersey,

Journal of Clinical Oncology

Abstract

The addition of oblimersen to dacarbazine significantly improved multiple clinical outcomes in patients with advanced melanoma and increased overall survival in patients without an elevated baseline serum LDH.

References

	Year	Citations

Page 1